Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma

Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demonstrate a...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy Vol. 11; pp. 6731 - 6740
Main Authors: Zhu, Zhenfeng, Xu, Litao, Zhuang, Liping, Ning, Zhouyu, Zhang, Chenyue, Yan, Xia, Lin, Junhua, Shen, Yehua, Wang, Peng, Meng, Zhiqiang
Format: Journal Article
Language:English
Published: New Zealand Dove Medical Press Limited 01-01-2018
Taylor & Francis Ltd
Dove Medical Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demonstrate a sensitive response to sorafenib. Therefore, it is valuable to determine the subgroups of patients who respond well as well as poorly to sorafenib. Thus, clinical variables of advanced HCC patients with sorafenib treatment were compiled to investigate whether monocyte-to-lymphocyte ratio (MLR) could be a biomarker for predicting sorafenib response. In this study, a total of 142 patients with advanced HCC were enrolled from January 1, 2013 to December 31, 2016 at the Fudan University Shanghai Cancer Center. MLR was analyzed using a ROC curve. A Cox regression model and log-rank test were performed to analyze the relationship between clinical factors and OS, as well as progression free survival (PFS). The optimal cut-off point for MLR was 0.35, and MLR level had no significant correlation with age, gender, hepatitis B infection, grade, alpha-fetoprotein (AFP) level and state of portal vein tumor thrombus. Multivariate Cox regression model showed that grade (HR: 0.608, 95% CI: 0.409-0.904, =0.014), AFP (HR: 0.445, 95% CI: 0.307-0.645, =0.0001), MLR (HR: 0.445, 95% CI: 0.301-0.658, =0.0001) and aspartate aminotransferase (AST) (HR: 1.005, 95% CI: 1.001-1.009, =0.007) may serve as independent prognostic predictors for OS, and MLR maintained significant correlation with PFS in HCC patients (HR: 0.457, 95% CI: 0.308-0.678, =0.0001). By log-rank test, there was longer PFS and OS in patients with low MLR than in those with high MLR (both =0.0001). MLR can predict sorafenib response and a high MLR is correlated with poor prognosis in patients with advanced HCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S173275